海外の治験の状況「1」での検索結果
2657件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder
- Schizophrenia;Schizoaffective disorder;Bipolar 1 disorder; Schizophrenia Schizoaffective disorder Bipolar 1 disorder;Mental Health - Schizophrenia;Mental Health - Other mental health disorders
- Australia
- 2019-11-13
Recruiting
- The CRADLE-4 Trial: Can planned early birth in pre-eclampsia (high BP in pregnancy) reduce pregnancy complications in India and Zambia, compared to watchful waiting?
- Timing of delivery in late preterm pre-eclampsia Pregnancy and Childbirth Pre-eclampsia
- India, Zambia
- 2019-11-28
Recruiting
- The use of an Autologous Platelet-rich Fibrin membrane in Urethroplasty for cases of Distal Hypospadias: A Randomized Controlled Trial
- Hypospadias;Hypospadias
- Egypt
- 2019-12-02
Authorised
- Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetes
- Diabetes Mellitus, Type 1 MedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Australia, Austria, Brazil, Canada, Denmark, European Union, Greece, Ireland, Israel, Russian Federation, Serbia, Spain, United Kingdom
- 2017-07-19
Not recruiting
- Aquatic Versus Land Based Exercise on Lymphedema Post Mastectomy
- Breast Cancer
- Egypt
- 2020-01-31
Recruiting
- Impact of Mobile Phone Diabetes Application on Diabetes Patients: a Randomized Controlled Trial
- Type 1 Diabetes Mellitus;Type 2 Diabetes Mellitus; Type 1 Diabetes Mellitus br>Type 2 Diabetes Mellitus;Metabolic and Endocrine - Diabetes
- Australia
- 2018-01-17
Not recruiting
- Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
- Hyperlipidemia
- Australia, Canada, France, Germany, Hong Kong, Netherlands, New Zealand, Norway, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
- 2013-01-07
Not recruiting
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- Australia, Korea, Republic of, Taiwan, United States
- 2014-08-20
Not recruiting
- Evaluation of RAS mutations in cell free deoxyribonucleic acid (cfDNA) in response to cetuximab anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer.
- Patients with histologically confirmed metastatic colorectal cancer.
- Australia
- 2015-07-24
Not Recruiting
- A trial comparing stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2 diabetic patients inadequately controlled on oral anti-diabetic therapy
- Diabetes Mellitus, Type 2 MedDRA version: 17.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Australia, Bulgaria, European Union, Hungary, India, Korea, Republic of, Serbia, Thailand, Turkey, United Arab Emirates
- 2015-04-02
Authorised
- An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) or Progressive Familial Intrahepatic Cholestasis (PFIC)
- Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) MedDRA version: 17.1 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 17.1 Level: PT Classification code 10053870 Term: Alagille syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Canada, United Kingdom, United States
- 2015-04-01
Recruiting
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia;BCR-ABL1 Fusion Protein Expression;Minimal Residual Disease;Philadelphia Chromosome Positive;T Acute Lymphoblastic Leukemia;Untreated Adult Acute Lymphoblastic Leukemia;Untreated Childhood Acute Lymphoblastic Leukemia
- Australia, Austria, Canada, Chile, China, Czechia, France, Germany, Italy, Netherlands, New Zealand, Puerto Rico, Saudi Arabia, Sweden, United Kingdom, United States
- 2016-12-28
Not recruiting
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
- Primary Cutaneous Anaplastic Large Cell Lymphoma;Mycosis Fungoides;Cutaneous T-Cell Lymphoma;Primary Cutaneous Anaplastic Large Cell Lymphoma;Mycosis Fungoides;Cutaneous T-Cell Lymphoma;Primary Cutaneous Anaplastic Large Cell Lymphoma;Mycosis Fungoides;Cutaneous T-Cell Lymphoma;Primary Cutaneous Anaplastic Large Cell Lymphoma;Mycosis Fungoides;Cutaneous T-Cell Lymphoma
- Australia, Austria, Belgium, Brazil, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States
- 2012-03-27
Not recruiting
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
- Locally Advanced or Metastatic Non Small Cell Lung Cancer
- Australia, France, Poland, United States
- 2012-01-31
Not recruiting
- A feasibility and efficacy study of anti-human Epidermal Growth Factor Receptor (Vectibix sequence) targeted EnGeneIC Delivery Vehicle (also known as EnGeneIC Dream Vector) containing clinician chosen therapeutic payload(s) (cytotoxic drug or functional nucleic acids) in patients with advanced cancer who have no curative treatment options.
- Advanced Solid tumours
- Australia
- 2013-11-13
Not Recruiting
- A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis
- Chronic Plaque type psoriasis
- Bulgaria, Czech Republic, Estonia, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
- 2013-10-24
Not Recruiting
- A clinical research study involving an experimental drug named Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide Single Tablet Regimen and Tenofovir Alafenamide Single Agent. This study evaluates if TAF SA is effective against HIV-1 infected subjects when added to subject’s current antiretroviral regimen that is no longer effective to treat HIV-1 and if subjects can safely switch to E/C/F/TAF STR plus atazanavir without increasing the amount of virus in their blood.
- HIV-1 Infection MedDRA version: 17.0 Level: LLT Classification code 10068341 Term: HIV-1 infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Canada, Dominican Republic, Germany, Poland, Russian Federation, South Africa, Thailand, Uganda, United Kingdom, United States
- 2013-09-20
Not recruiting
- A Blood Diagnostic test for epidermal growth factor receptor (EGFR) mutations
- EGFR Mutation Blood Test Evaluation in Non Small Cell Lung Cancer
- Australia
- 2013-07-03
Recruiting
- A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
- Advanced Solid Tumors Cancer
- Australia, Israel, United States
- 2017-07-27
Authorised
- Open-label, randomized study of two doses of GSK2857916 in participants with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-CD38 antibody
- Relapsed/Refractory Multiple Myeloma MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Germany, Italy, Spain, United Kingdom, United States
- 2018-05-14